<DOC>
	<DOCNO>NCT01086735</DOCNO>
	<brief_summary>The main complication allogeneic hematopoietic stem cell transplantation ( HSCT ) include graft-versus-host disease ( GVHD ) poor immune reconstitution lead severe infection leukemia relapse . Mature donor T-cells present transplant facilitate T-cell reconstitution also induce GVHD , impair immune reconstitution . We develop strategy alloreactive T-cell depletion , use T-cells express Herpes simplex thymidine kinase ( TK ) suicide gene combine ganciclovir ( GCV ) treatment . This system permit selective elimination divide TK+ T-cells vivo . To test hypothesis preclinical setting , previously develop several experimental model GVHD use TK+ T-cells mouse . The demonstration preventive treatment GCV administer close time HSCT could control GVHD bring proof concept . We propose clinical trial test whether donor lymphocyte infusion ( DLI ) use TK-transduced cell permit induce graft-versus-tumor ( GVT ) effect treatment relapse HSCT , GVHD control GCV treatment .</brief_summary>
	<brief_title>Suicide Gene Therapy Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>DLI-TK administer either failure 1 several previous standard ( std- ) DLI , define minimal follow-up 2 month last injection . To prepare DLI-TK , donor T-cells transduce retroviral vector encode TK . Transduced cell select use CliniMACS device ( MYLTENYI ) . In case previous std-DLI receive , DLI-TK cell dose adjust equal maximal cell dose previously receive std-DLI . No comparison plan analysis .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Suicide</mesh_term>
	<criteria>Hematological malignancy . Previous allogeneic hematopoietic stem cell transplantation . Relapse diagnose molecular , cytogenetic , cytological level . Failure previous stdILD inclusion first intention without previous stdDLI . Age &gt; 18 year &lt; 70 year time inclusion . For patient 15 18 year age , caseper case inclusion study . Performance status consider score Eastern Cooperative Oncology Group ( ECOG ) &lt; 2 . Life expectation 1monthold superior . Signed write informed consent . Negative human chorionic gonadotropin ( HCG ) 7 day precede inclusion woman age procreation . Membership French national insurance . Grade &gt; II acute GVHD chronic extensive GVHD time inclusion . Patient receive immunosuppressive treatment GVHD treatment time inclusion . Dysfunction liver ( alanine aminotransferase / aspartate transaminase ( ALAT/ASAT ) &gt; 5 N , bilirubin &gt; 50 ÂµM ) , renal function ( creatinine clearance &lt; 30 ml / min ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>hematological malignancy</keyword>
	<keyword>allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>donor lymphocyte infusion</keyword>
	<keyword>antitumor immunotherapy</keyword>
	<keyword>graft-versus-tumor effect</keyword>
	<keyword>gene therapy</keyword>
	<keyword>relapse</keyword>
	<keyword>adult</keyword>
</DOC>